Background. (Lancet 1998;352: 257-63) 
Meta-analysis was developed as a technique to sumtrials (1000 patients or more) with the results of metaanalyses published earlier on the same topics. 2 They marise the results of multiple related studies. A good identified 12 large randomised controlled trials and meta-analysis requires a systematic approach to the 19 meta-analyses addressing the same questions. The identification and abstracting of critical information agreement between the meta-analyses and the large from each report being analysed. Investigators must trials was only fair (kappa=0.35). The positive preidentify all relevant studies by carefully reviewing data dictive value (PPV) of meta-analysis was 68% and the bases and bibliographies and by seeking out unpublished negative predictive value (NPV) was 67%. Accordingly, reports. This technique allows inclusion of small studies if there had been no subsequent randomised trial, the and both published and unpublished trials. Unpublished meta-analysis would have led to the adoption of intrials are included in an effort to avoid publication bias.
effective treatment in 32% of cases (100% minus the Ideally, reports in other languages are included.
1 Proper PPV) and to rejection of a useful treatment in 33% of use of this methodology necessitates extensive colcases (100% minus the NPV). In all cases of dislaboration between clinicians and statisticians. When agreement a statistically significant effect of treatment performed correctly, meta-analysis should provide us was found by either the meta-analysis or the larger with the "best estimate" of the answer to the question randomised trial and no significant effect by the other under evaluation.
method. In no case was there a divergence in which Large randomised prospective clinical trials are conthe large randomised trial and the meta-analysis gave sidered the "gold standard" and are assigned the highest statistically significant and opposite answers-that is, a level of evidence when developing clinical guidelines. positive effect to a detrimental effect. 
Strengths and weaknesses of the postoperative
to treat basis. In addition to the main conclusion that postoperative radiotherapy was detrimental, no subradiotherapy (PORT) meta-analysis In the meta-analysis discussed in the Introductory Artgroup analysis based on age, sex, or histology demicle 3 the authors conclude that postoperative radioonstrated a benefit with treatment. Additionally, analysis therapy (PORT) in patients with completely resected based on disease stage did not show a beneficial effect non-small cell lung cancer had a statistically significant of PORT in patients with stage I, II, or III. adverse effect on survival (hazard ratio (HR) 1.21 (95% Are there any weaknesses? Definitely yes! The analysis CI 1.08 to 1.34)) and reduced overall survival at two includes studies that were performed over a 30 year years from 55% to 48% (figs 1 and 2).
period . The total dose of radiotherapy varied What are the strengths of the PORT meta-analysis? from 30 to 60 Gy and the number of treatment fractions The study was conducted by an outstanding group of varied from 10 to 30. The radiation sources employed investigators with a well established track record in varied from cobalt 60 (gamma ray teletherapy) to linear this type of analysis. They performed a comprehensive accelerator (megavoltage x ray therapy). Of importance literature review and included both published and unis the fact that only one trial used computed tomographic published trials. They used updated information on planning of radiotherapy. The differences in the number survival, recurrence, date of last follow up, details of of fractions, dose per fraction, total dose, as well as treatment allocation, randomisation, age, sex, cell type, source of radiation and other quality control issues such stage, and performance scores. Information was obas portal size and percentage of total planned dose tained for all randomised patients including those who delivered to the port could all influence the outcomes had been excluded from the investigator's original anaof the individual trials. lyses. All trials included were analysed on an intention An additional weakness of the analysis is the inclusion of patients with a performance score (PS) of 2, 3, or 4. Of the 488 patients with a known performance score, 160 were PS 2, 3, or 4. In current clinical trials patients with a PS of 3 or 4 are almost never enrolled because of excessive treatment related morbidity and mortality in these poor risk individuals. Especially problematic is the fact that PS was not known for patients enrolled in six of the clinical trials included in the analysis. It is also unclear whether the various trials stratified treatment based on PS.
Finally, 15% of deaths in the individuals randomised to PORT were due to non-cancer and non-treatment related causes while only 9% of deaths in the surgery only group were due to these factors. Was this difference due to the chance occurrence of more cardiovascular or other disease in the PORT group compared with the no-PORT group? Probably not, but we do not really know because the trials were not controlled for comorbid conditions. This difference in non-cancer deaths in the two arms suggests that 6% of the patients in the radiotherapy group were dying even though these were suggests real quality control issues related to the PORT group.bmj.com on June 23, 2017 -Published by http://thorax.bmj.com/ Downloaded from and it would be interesting to know if more of these deaths due to "other causes" were observed in the earlier trials from the late 1960s and early 1970s.
Review of selected articles included in the PORT meta-analysis
The Belgium trial reported by VanHoutte and colleagues enrolled 224 patients from 1966 to 1975. 4 All patients had a curative resection defined as "the tumour must be completely removed without extension beyond the lung and without invasion of the lymph nodes". One week after surgery patients were randomised to receive adjuvant radiotherapy (PORT) or no PORT. The radiation source was a cobalt 60 unit and the dose was 6000 cGy in 30 fractions. Only 175 patients of the initial 224 were evaluable. Radiation treatment was not performed in 12 patients randomised to radiotherapy. The five year survival was lower in the PORT group Patients were carefully staged as patients randomised to radiotherapy but who did not T1N1M0, T2N1M0, T1N2M0, and T2N2M0. They receive treatment were included in the analysis. While were stratified by surgeon, TNM stage, and histology. this trial was superb for its time, there are numerous
The radiation dose was 40 Gy in 15 fractions using problems with design, implementation, and analysis either cobalt 60 or linear accelerator. At the time of the based on the standards of the 1990s. report 72% of the 308 patients had died. The survival The Lung Cancer Study Group randomised 230 curves were overlapping with a hazard ratio of 1.00 (p= patients with stage II or III totally resected squamous 0.99; fig 4) . Overall, the time to local recurrence did cell cancer to observation or PORT from 1978 to 1985. 5 not differ between the two arms (HR 1.23, 95% CI A total of 50 Gy was delivered in 1.8-2.0 Gy daily 0.87 to 1.73, p=0.24). In subgroup analysis the N2 fractions. The radiation sources were either cobalt 60 group receiving PORT appeared to have a delayed time or linear accelerators. Of 230 patients randomised, 210 to local recurrence. were eligible. Ineligibility (17 of 20) was due mainly to This trial was well designed, conducted, and analysed. non-squamous histology at the time of pathological The PORT group did have treatment related toxicity, review. Of 210 patients, 10 did not receive the assigned including 15 classified as severe, but there were no radiotherapy and three of those assigned to no radiotreatment related deaths. The authors themselves contherapy demanded treatment. The time to local tumour cluded that radiation toxicity was "not of sufficient recurrence favoured the PORT arm but was not statistically significant (p=0.188). The overall survival of the two groups was identical with overlapping curves (fig 3) . The number of non-cancer deaths in the PORT arm included six from respiratory failure and five from cardiac failure while in the control arm there were three deaths from respiratory failure and two from cardiac failure. Subset analysis, with all its potential problems, suggested a reduced local recurrence rate in patients with resected N2 disease; however, no survival benefit was observed with radiotherapy in any nodal disease subgroup.
This trial had an excellent design and careful analysis with a less than 10% ineligibility rate. Two potential weaknesses of the trial were that it took seven years to complete and included only squamous cell histology, thereby raising the question of how applicable it is to of this trial are convincing in that PORT does not group.bmj.com on June 23, 2017 -Published by http://thorax.bmj.com/ Downloaded from magnitude to be regarded as a contraindication to treatradiotherapy (50 Gy/28 fractions), with or without four ment". They also point out that the radiotherapy dose cycles of concurrent chemotherapy with etoposide and and techniques used would not currently be regarded cisplatin. All patients had careful mediastinal lymph as ideal. The midline mediastinal nodes received a lower node staging. It took over six years to enroll 480 patients. dose as a result of posterior spinal cord shielding. In
There was absolutely no difference in survival between the USA a dose of 60 Gy in 30 fractions over six weeks patients receiving radiotherapy alone and those receiving would be considered a more standard regimen.
the combined modality therapy. When this trial was launched adjuvant radiotherapy was commonly employed in resected patients with N1 or N2 disease even Role of postoperative adjuvant chemotherapy though it had not been shown to improve survival. A now classic meta-analysis was performed in colAccordingly, investigators did not believe that it would laboration between the Medical Research Council Canbe possible to conduct a trial with a "no treatment" cer Trials Office and Institute Gustave Roussy.
7 They arm in North America. Because of the public's perevaluated trials from 1965 to the end of 1991. Patients ception that treatment is better than no treatment, it with early stage disease underwent surgical resection was decided to give radiotherapy to all patients and to and were randomised to receive systemic chemotherapy ask the additional chemotherapy question. The answer or no treatment. Eight of the more recent trials, which to that question is that etoposide/cisplatin chemotherapy included almost 1400 patients, used cisplatin based does not add to survival in patients with totally resected combination chemotherapy and five older trials used disease.
9 alkylating agents (mainly cyclophosphamide and nitroIn North America there are currently two adjuvant sourea). The results of the trials involving surgery folchemotherapy trials underway for totally resected dislowed by alkylating agents were all consistent with worse ease. The National Cancer Institute of Canada has an survival in the adjuvant chemotherapy arms. The hazard intergroup trial (BR10) that randomises patients with ratio was 1.15 (p=0.005) in favour of surgery alone.
totally resected non-small cell lung cancer (T2N0M, For regimens containing cisplatin the hazard ratio es-T1N1M0, T2N1) to receive four cycles of cisplatin timates for most trials favoured chemotherapy, with an (50 mg/m 2 on days 1 and 8) and weekly vinorelbine overall hazard ratio of 0.87 (p=0.08) or a 13% reduction (25 mg/m 2 for 16 weeks) or observation only. The goal in the risk of death, suggesting an absolute benefit from of the study is to compare disease free and overall chemotherapy of 5% at five years.
survival in the two groups and to compare the quality In the same meta-analysis the authors evaluated ranof life for treatment versus no treatment. domised trials of surgery plus radiotherapy versus sur-A second adjuvant chemotherapy trial is being congery plus radiotherapy plus chemotherapy. The overall ducted by the Cancer and Acute Leukemia Group B in hazard ratio of 0.94 was marginally in favour of chemocollaboration with other cooperative oncology groups. therapy (p=0.46). Collectively, these meta-analyses
Patients with T2N0M0 non-small cell lung cancer are suggest that adjuvant chemotherapy after surgery alone randomised either to observation alone or to treatment or surgery and radiotherapy adds marginally to survival.
with 10 11 These two trials are the best does, however, support the need for more studies to available on the effect of neoadjuvant chemotherapy evaluate adjuvant chemotherapy, especially with new and both show that preoperative chemotherapy followed agents, for patients with stage IB, IIA/B, and IIIA totally by surgery is better than surgery alone for stage IIIA resected non-small cell lung cancer. Current ongoing disease. Currently, a large North American intergroup trials are outlined above, and it is possible that these trial is underway to evaluate both chemotherapy and studies may change the current recommendation of no radiotherapy with or without surgery for stage IIIA adjuvant therapy for totally resected early stage disease. disease. This trial will help answer the question about the role of surgery in patients with stage IIIA disease,
